India Story Tempered? Government May Put Future Brownfield Buyouts Under Scrutiny; No Qualms On Greenfield Investments
This article was originally published in PharmAsia News
MUMBAI - Whether increased acquisitions of large Indian companies by multinational companies presents a threat to public health is being considered by a high-level inter-ministerial group that may approve provisions that distinguish between "greenfield" and "brownfield" investments made in India by external organizations or agencies
You may also be interested in...
After A Brief Pause, Injectables Cash Cow Agila Is Back Into Production; Pfizer Expects Shipping To Commence Soon
Agila, as its name suggests, was agile in correcting deficiencies outlined in an FDA 483 last month and is back on track to supply global customers like Pfizer, GSK and Eli Lilly. But Mylan’s planned buyout of Agila, Strides Arcolab’s cash cow, has hit a snag and been put on hold by India’s finance ministry.
Fresh doubts have been raised on whether to allow foreign investments in Indian companies, pitting two powerful government ministries on opposing sides of the battle.
MUMBAI - The Indian government has decided to route all foreign direct investments in existing Indian companies via the Foreign Investment Promotion Board, a surprising move that could have far-reaching implications on big ticket M&As in the country's pharmaceutical industry